Bacteriophage Microcapsules for Stability and Controlled Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for encapsulating bacteriophages are inefficient, leading to instability, rapid clearance by the immune system, and lack of specificity, which affects the effectiveness of phage therapy in treating bacterial infections.
Innovation Solution
Encapsulating bacteriophages in biodegradable amino acid-based polymeric microparticles, such as Polyester amide urea (PEAU) or leucine-based poly ester amide polymers, which provide stability, controlled release, and protection from enzymatic or acidic degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bacteriophages are encapsulated in conventional polymers like PGLA, alginate, chitosan, or pectin, then the phages are protected to some extent, but they lose stability and integrity after 7 days due to physical interaction at the surface or within the porous matrix
Solution Approach 1:
The patent uses a composite polymer system comprising poly(D,L-lactide-co-glycolide) (PGLA) combined with hydroxypropyl cellulose (HPC) and gelatin. This composite formulation creates a non-porous matrix that prevents physical interaction between phages and the polymer surface, thereby maintaining phage stability and integrity for extended periods beyond 7 days while providing controlled release capabilities.
2Device complexity
If bacteriophages are delivered in simple liquid formulations, then the delivery system is simple, but the phages are rapidly cleared by the immune system and inactivated by environmental factors such as enzymes, pH, and temperature
Solution Approach 1:
The patent employs biodegradable polymeric microcapsules as flexible protective shells that encapsulate bacteriophages. These microcapsules provide a physical barrier that protects phages from enzymatic degradation, pH variations, and temperature fluctuations in the environment, while allowing controlled release at the target site. The microcapsule structure significantly extends phage circulation time and reduces systemic clearance by the immune system.
3Reliability
If bacteriophages are encapsulated in liposomes, then the delivery system provides some protection, but liposomes are thermodynamically unstable and tend to fuse, resulting in early release of the therapeutic agent
Solution Approach 1:
The patent changes the fundamental parameters of the encapsulation material from lipid-based (liposomes) to polymer-based (PGLA-HPC-gelatin composite). This parameter change transforms the formulation from thermodynamically unstable liposomes that fuse and release contents prematurely to kinetically stable polymer microcapsules with non-porous matrices that prevent phage leakage and maintain structural integrity throughout the intended delivery period.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The encapsulation method enhances the therapeutic activity of bacteriophages by prolonging their presence in the body, increasing circulation time, and protecting them from degradation, allowing for targeted and sustained delivery to bacterial infections.
Implementation Method 1
Encapsulating bacteriophages in biodegradable amino acid-based polymeric microparticles, such as Polyester amide urea (PEAU) or leucine-based poly ester amide polymers, which provide stability, controlled release, and protection from enzymatic or acidic degradation.
Implementation Method 2
biodegradable amino acid-based polymeric microparticles... allow for high phage loading and have a proper phage release rate
Data Source
AI summary
An encapsulated bacteriophage formulation and a method for encapsulating bacteriophages and bacteriophage-related products in polymeric microcapsules is provided. Some embodiments of the method of producing the encapsulated bacteriophages involves a water-in-oil-in-water double emulsion.